Clinical trial · Observational
Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study
NCT06484127CI-TRIAL-00078479completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to reveal the predictive value of spatial heterogeneity and maturity difference of tertiary lymphoid structure in pathological sections of prostate cancer patients for clinical features and prognosis. It provides a new idea for the selection of prostate cancer immunotherapy population in the future.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- tertiary lymphoid structure positive patients
- label
- tertiary lymphoid structure negative patients
Primary outcomes (1)
- measure
- Correlation between the detection of TLS(tertiary lymphoid structure) and clinical features
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: 1.patients diagnosed with prostate cancer who underwent radical prostatectomy or prostate puncture Exclusion Criteria: 1\. incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.